These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Recombinant human IGF-1 prevents type 1 diabetes in female non-obese diabetic mice].
    Author: Liu F, Yu M, Zhu Q.
    Journal: Zhonghua Yu Fang Yi Xue Za Zhi; 2000 Sep; 34(5):281-3. PubMed ID: 11372396.
    Abstract:
    OBJECTIVES: To study whether recombinant human (rhIGF-1) can prevent the onset of type 1 diabetes in female non-obese diabetic (NOD) mice, and its influence on their immune system. METHODS: Ten mice were injected intraperitonally (i.p.) rhIGF-1 37.5 micrograms.kg-1.d-1 at 4 weeks old for 2 weeks at treated group; and the same volume of normal solution (NS) was used in 10 mice as control group. All mice were killed at 40 weeks old or 2 weeks after the diagnosis of diabetes. Blood glucose of tail vein blood was measured weekly using a glucometer. At the end of the experiment, serum C-peptide levels and antibodies to glutamic acid decarboxylase (GAD) were detected with RIA and ELISA methods, respectively. T cell subsets of spleen were undertaken two-color FACS analysis using Cy-chrome anti-CD4 and FITC-anti-CD8 monoclonal antibodies; pancreatic histopathology and immunohistochemistry of T cell were conducted. RESULTS: Treatment with rhIGF-1 at 4 weeks old reduced the total incidence of diabetes (40% vs 90%, P < 0.05) and delay its onset [(26.25 +/- 3.68) weeks vs (21.6 +/- 6.7) weeks] compared with control group (P < 0.05). RhIGF-1 showed the growth effect on NOD mice, because the wet weight of spleen and pancreas of groups treated with rhIGF-1 were higher than that of control mice (P < 0.01, respectively). Only 3.24 (0.92 islets/mouse) was observed in the control group at death, but they increased to 13.2 (3.14 islets/mouse) in the rhIGF-1 group. The insulitis score decreased from 0.738 +/- 0.194 to 0.098 +/- 0.035 in the later group. A marked reduction of insulitis severity of pancreatic glands was also observed. A strong proliferative response of CD8+ T subsets in splenocytes occurred in rhIGF-1 treated mice, and the imbalance of CD4+/CD8+ subgroup in control mice (2.03 +/- 0.72) was corrected in the later group (0.53 +/- 0.22, respectively, P < 0.01). The lymphocytes infiltrating islets in the rhIGF-1 group showed a reduction of CD4+ cells, and they existed only outside of islets. CONCLUSIONS: These data demonstrated the preventive effects of rhtIGF-1 on the onset of type 1 diabetes and the severity of insulitis in female NOD mice. The mechanisms of these effects may be related to the induction of a CD8+ Ts cell response that inhibits the spontaneous development of autoreactive CD4+ T subsets response, or inhibiting the homing of CD4+ T cells to islets.
    [Abstract] [Full Text] [Related] [New Search]